The effect of Cinnarizine on Autism

Interventional comparison of the effect of cinnarizine with placebo on mood swings and self-harm and stereotyped behaviors of autistic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110628006907N16

Enrollment

Registered

2022-01-07

Start date

2022-01-20

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autism spectrum disorder. Autistic disorder

Interventions

Intervention 1: Intervention group (17 patients): Receiving Cinnarizine 10-15 mg/kg once daily for 3 months. Intervention 2: Control group (17 patients): Receiving placebo 10-15 mg/kg once daily for 3

Eligibility

Sex/Gender

All

Age

2 Years to 7 Years

Inclusion criteria

Inclusion criteria: Age between 2-7 years old Diagnosed with Autism based on DSM5 criteria which is approved by a psychiatrist

Exclusion criteria

Exclusion criteria: Conditions other than Autism justifying the symptoms of patient

Design outcomes

Primary

Measure	Time frame
Patient's score from the Behavioral problems questionnaire for people with intellectual disabilities. Timepoint: at the beginning of trial and 3 months later. Method of measurement: Behavioral problems questionnaire for people with intellectual disabilities.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahmoudreza Ashrafi

Tehran University of Medical Sciences

ashrafim@tums.ac.ir+98 21 6612 9252

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026